Skip to main content
OpenTrials
Completed

NCT Number: NCT01441635

Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids

The purpose of this proof-of-concept study is to assess the safety and effectiveness of elagolix versus placebo to reduce uterine bleeding associated with uterine fibroids, and to reduce fibroid volume and uterine volume in premenopausal women 20 to 49 years of age with heavy uterine bleeding.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Heavy Uterine Bleeding Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Hemorrhage Leiomyoma Menorrhagia Menstruation Disturbances Neoplasms Neoplasms by Histologic Type Neoplasms, Connective and Soft Tissue Neoplasms, Muscle Tissue Pathologic Processes Pathological Conditions, Signs and Symptoms Urogenital Diseases Uterine Diseases Uterine Fibroids Uterine Hemorrhage

Age range

20 year–49 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is a pre-menopausal female 20 to 49 years of age.
  • Subject has a diagnosis of uterine fibroids documented by a pelvic ultrasound assessed by a central reader and verification that a fibroid present met the following criteria:
  • At least 1 fibroid with diameter ≥ 2 cm (longest diameter), or multiple small fibroids with a total uterine volume of ≥ 200 cm³ to ≤ 2,500 cm³ (approximately 22 weeks' gestation) as documented by a centrally read ultrasound.
  • Only intramural, submucosal non-pedunculated, and subserosal fibroids qualified subjects for enrollment (intracavitary pedunculated fibroids were exclusionary).
  • Ultrasound procedures were performed during the Screening Period, and subjects were not randomized until the investigator reviewed the central reader results verifying the inclusion requirements.
  • Subject has a history of regular menstrual cycles between 24 to 35 days.
  • Subject has heavy uterine bleeding associated with uterine fibroids as evidenced by blood loss > 80 mL during 2 screening menstrual cycles, measured by the alkaline hematin method.

Exclusion criteria

  • Subject has had a myomectomy, uterine artery embolization, or high intensity focused ultrasound for fibroid destruction within 1 year prior to randomization or any history of endometrial ablation.
  • Subject has a history of osteoporosis or other metabolic bone disease.
  • Subject shows evidence of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric (including depression), or neurologic diseases or any uncontrolled medical illness such as uncontrolled type 2 diabetes.
  • Subject has a history of clinically significant condition(s) including but not limited to:
  • Endometriosis
  • Epilepsy or seizures
  • Type 1 diabetes
  • Any cancer (except basal cell carcinoma of the skin), including breast or ovarian cancer or subject has taken any systemic cancer chemotherapy

Treatment and study plan

Elagolix

Drug

Elagolix tablets

Other names: ABT-620

Placebo

Drug

Matching placebo tablets

Estradiol/Norethindrone acetate (E2/NETA)

Drug

A continuous once-daily oral tablet containing estrogen and progestin; the low-dose strength contains estradiol 0.5 mg and norethindrone acetate 0.1 mg.

Other names: Activella®

Estradiol

Drug

1.0 mg micronized estradiol tablets administered once a day

Other names: Estrace®

Progesterone

Drug

Progesterone 200 mg administered during the last 12 days of the 28-day menstrual cycle

Other names: Prometrium®

Primary outcomes

  1. Mean Change From Baseline to the Last 28 Days of Treatment in Menstrual Blood Loss (MBL)

    Time frame: Baseline (last menstrual cycle during the screening period) and the last 28 days of treatment (approximately days 61 to 90)

    The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.

    Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero.

Secondary outcomes

  1. Percent Change From Baseline to the Last 28 Days of Treatment in Menstrual Blood Loss (MBL)

    Time frame: Baseline (last menstrual cycle during the screening period) and the last 28 days of treatment (approximately days 61 to 90)

    The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.

    Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero.

  2. Percentage of Participants With MBL < 80 mL and With a ≥ 50% Reduction From Baseline in MBL During the Last 28 Days of Treatment

    Time frame: Baseline (last menstrual cycle during the screening period) and the last 28 days of treatment (approximately days 61 to 90)

    The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.

    Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero.

  3. Percentage of Participants With MBL < 80 mL During the Last 28 Days of Treatment

    Time frame: The last 28 days of treatment (approximately days 61 to 90)

    The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.

    Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero.

  4. Percentage of Participants With a ≥ 50% Reduction From Baseline in MBL During the Last 28 Days of Treatment

    Time frame: Baseline (last menstrual cycle during the screening period) and the last 28 days of treatment (approximately days 61 to 90)

    The alkaline hematin method was used for the assessment of MBL. Sanitary products were collected at screening and for any spotting or bleeding episodes that occurred during treatment.

    Participants with missing MBL volume for the last treatment period and no bleeding indicated in the electronic daily bleeding diary (eDiary) in the last treatment period, and participants with no post-baseline MBL data were assigned an MBL value of zero.

  5. Percentage of Participants With No Change, Decrease From Baseline, or Increase From Baseline in Hemoglobin at Month 3

    Time frame: Baseline and Month 3

    The percentage of subjects with changes in hemoglobin concentration from Baseline to Month 3 in each of the following categories:

    • No change from baseline in hemoglobin
    • Decrease from baseline in hemoglobin ≥ -0.5 g/dL
    • Decrease from baseline in hemoglobin ≥ -1.0 g/dL
    • Increase from baseline in hemoglobin ≥ 0.5 g/dL
    • Increase from baseline in hemoglobin ≥ 1.0 g/dL

    The above categories are not all mutually exclusive or exhaustive.

  6. Change in Hemoglobin Concentration From Baseline to Month 3

    Time frame: Baseline and Month 3

  7. Change From Baseline to Month 3 in Uterine Bleeding Score

    Time frame: Baseline (average bleeding score over the 30 days prior to first dose) and month 3 (average bleeding score over days 61 to 90)

    Participants recorded the previous days' presence and severity of bleeding every morning in an electronic diary (eDiary) according to the Mansfield-Voda-Jorgenson Menstrual Bleeding Scale:

    • 1 (Spotting): A drop or 2 of blood, not even requiring sanitary protection.
    • 2 (Very light): Needing to change the least absorbent tampon or pad 1 to 2 times per day.
    • 3 (Light): Needing to change a low or regular absorbency tampon or pad 2 or 3 times per day.
    • 4 (Moderate): Needing to change a regular absorbency tampon or pad every 3 to 4 hours.
    • 5 (Heavy): Needing to change a high absorbency tampon or pad every 3 to 4 hours.
    • 6 (Very heavy/gushing): Very heavy bleeding, protection hardly works at all; needing to change the highest absorbency tampon or pad every hour or 2.

  8. Change From Baseline to Month 3 in Percentage of Days With Any Uterine Bleeding

    Time frame: Baseline (average bleeding score over the 30 days prior to first dose) and month 3 (average bleeding score over days 61 to 90)

    Participants recorded the previous days' presence and severity of bleeding every morning in an electronic diary (eDiary) according to the Mansfield-Voda-Jorgenson Menstrual Bleeding Scale:

    • 1 (Spotting): A drop or 2 of blood, not even requiring sanitary protection.
    • 2 (Very light): Needing to change the least absorbent tampon or pad 1 to 2 times per day.
    • 3 (Light): Needing to change a low or regular absorbency tampon or pad 2 or 3 times per day.
    • 4 (Moderate): Needing to change a regular absorbency tampon or pad every 3 to 4 hours.
    • 5 (Heavy): Needing to change a high absorbency tampon or pad every 3 to 4 hours.
    • 6 (Very heavy/gushing): Very heavy bleeding, protection hardly works at all; needing to change the highest absorbency tampon or pad every hour or 2.

    A day with any uterine bleeding is defined as a days with a bleeding score ≥ 1.

  9. Change From Baseline to Month 3 in Percentage of Days With Moderate to Very Heavy Bleeding

    Time frame: Baseline (average bleeding score over the 30 days prior to first dose) and month 3 (average bleeding score over days 61 to 90)

    Participants recorded the previous days' presence and severity of bleeding every morning in an electronic diary (eDiary) according to the Mansfield-Voda-Jorgenson Menstrual Bleeding Scale:

    • 1 (Spotting): A drop or 2 of blood, not even requiring sanitary protection.
    • 2 (Very light): Needing to change the least absorbent tampon or pad 1 to 2 times per day.
    • 3 (Light): Needing to change a low or regular absorbency tampon or pad 2 or 3 times per day.
    • 4 (Moderate): Needing to change a regular absorbency tampon or pad every 3 to 4 hours.
    • 5 (Heavy): Needing to change a high absorbency tampon or pad every 3 to 4 hours.
    • 6 (Very heavy/gushing): Very heavy bleeding, protection hardly works at all; needing to change the highest absorbency tampon or pad every hour or 2.

    A day with moderate to very heavy bleeding is defined as a days with a bleeding score ≥ 3.

  10. Percentage of Participants With Any Uterine Bleeding or Moderate to Very Heavy Uterine Bleeding at Month 3

    Time frame: Month 3 (average bleeding score over days 61 to 90)

    Participants recorded the previous days' presence and severity of bleeding every morning in an eDiary according to the Mansfield-Voda-Jorgenson Menstrual Bleeding Scale:

    • 1 (Spotting): A drop or 2 of blood, not even requiring sanitary protection.
    • 2 (Very light): Needing to change the least absorbent tampon or pad 1 to 2 times per day.
    • 3 (Light): Needing to change a low or regular absorbency tampon or pad 2 or 3 times per day.
    • 4 (Moderate): Needing to change a regular absorbency tampon or pad every 3 to 4 hours.
    • 5 (Heavy): Needing to change a high absorbency tampon or pad every 3 to 4 hours.
    • 6 (Very heavy/gushing): Very heavy bleeding, protection hardly works at all; needing to change the highest absorbency tampon or pad every hour or 2.

    Any bleeding is defined as a score ≥ 1 and moderate to very heavy bleeding is defined as a score ≥ 3.

  11. Percentage of Participants With Suppression of Bleeding (Spotting Allowed) or Amenorrhea During the Last 56 Days of Treatment

    Time frame: The last 56 days of treatment (approximately days 33 to 90)

    Suppression of bleeding is defined as no record of bleeding (spotting allowed) in the e-diary and no record of bleeding Indicated in the alkaline hematin data during the last 56 days of treatment.

    Amenorrhea is defined as no record of bleeding or spotting indicated in the e-diary and no record of bleeding or spotting Indicated in the alkaline hematin data during the last 56 days of treatment.

  12. Percent Change From Baseline to Month 3 in Uterine Volume

    Time frame: Baseline and month 3

    Uterine volume was determined using transabdominal ultrasound. The images were analyzed by a central imaging center.

  13. Percentage of Participants With ≥ 25% Reduction in Uterine Volume at Month 3 / Final Visit

    Time frame: Baseline and month 3 or the final visit during the treatment period for participants who prematurely discontinued.

    Uterine volume was determined using transabdominal ultrasound. The images were analyzed by a central imaging center.

  14. Percent Change From Baseline to Month 3 in Volume of the Largest Fibroid

    Time frame: Baseline and month 3

    The volume of the largest fibroid was determined using transabdominal ultrasound. The images were analyzed by a central imaging center.

  15. Percentage of Participants With ≥ 25% Reduction in Volume of Largest Fibroid at Month 3 / Final Visit

    Time frame: Baseline and month 3 or the final visit during the treatment period for participants who prematurely discontinued.

    The volume of the largest fibroid was determined using transabdominal ultrasound. The images were analyzed by a central imaging center.

  16. Change From Baseline to Month 3 in the Uterine Fibroid Symptom Quality of Life Questionnaire (UFS-QoL)

    Time frame: Baseline and month 3

    The UFS-QoL is a disease-specific, self-administered, validated questionnaire developed to evaluate the symptoms associated with uterine fibroids and their impact on health-related quality of life (HRQL) in women with symptomatic uterine fibroids. The questionnaire consists of 37 questions, divided into 2 parts: 1) an 8-item symptom severity scale and 2) a 29-item HRQL subscale comprising 6 domains (concern, activities, energy/mood, control, self-consiousness, and sexual function), with a 4-week recall. All items are scored on a 5-point scale, ranging from "not at all" to "a very great deal" for symptom severity items and "none of the time" to "all of the time" for the HRQL items. Symptom severity and HRQL subscale scores were summed and transformed into a 0 to 100 point scale to provide a total score for each of the 2 components.

    Lower symptom severity scores indicate better quality of life and higher total HRQL scores indicate better quality of life.

  17. Change From Baseline to Month 3 in the Uterine Fibroids Daily Symptom Scale Scores

    Time frame: Baseline (average score over the 30 days prior to first dose) and month 3 (average score over days 61 to 90)

    The uterine fibroid daily symptom scale is self-administered questionnaire, with a scale that ranges from 0 to 10 for the symptoms of pelvic pain, fatigue, and cramping and the impact of uterine fibroids on the subject's daily life, with 0 being the absence of the symptom and 10 being the worst severity of the symptoms or completely preventing the subjects from performing daily activities. Participants self-reported values daily in the e-Diary.

  18. Change From Baseline to Month 3 in the Subject Surgery Intention Questionnaire (SSIQ) Version 2.0

    Time frame: Baseline and month 3

    The Subject Intention Questionnaire (SSIQ) is a non-validated, exploratory questionnaires intended to evaluate the subject's intent to undergo surgical procedures if current endometriosis-associated symptoms continued. The scoring scale ranged from 0 (not at all likely to consider surgery) to 10 (very likely to consider surgery).

    SSIQ included the 2 following questions:

    • How likely are you to consider having myomectomy surgery to treat your uterine fibroid if your symptoms continue as they are now?
    • How likely are you to consider hysterectomy surgery if your uterine fibroid symptoms continue as they are now?

  19. Change From Baseline to Month 3 in the Physician Surgery Intention Questionnaire (PSIQ) Version 2.0

    Time frame: Baseline and month 3

    The Physician Intention Questionnaire (PSIQ) is a non-validated, exploratory questionnaire intended to evaluate the investigator's intent to recommend surgical procedures if current endometriosis-associated symptoms continued. The scoring scale ranged from 0 (not at all likely to recommend surgery) to 10 (very likely to recommend surgery).

    The PSIQ included the 2 following questions:

    • How likely are you to recommend myomectomy to treat this patient's uterine fibroid if her symptoms continue as they are now?
    • How likely are you to recommend definitive surgery hysterectomy for this patient if her uterine fibroid symptoms continue as they are now?

Sponsors and collaborators

Lead sponsor

AbbVie (prior sponsor, Abbott)

Industry

Registry information

Official study title

Phase 2a Proof Of Concept Study to Evaluate the Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids

Important dates

Study start
2011
Primary completion
2013
Study completion
2014
First posted
Sep 28, 2011
Registry last updated
Jul 13, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.